32 results on '"Kobinger, Gary P."'
Search Results
2. Antibody therapeutics for Ebola virus disease.
- Author
-
Zeitlin, Larry, Whaley, Kevin J, Olinger, Gene G, Jacobs, Michael, Gopal, Robin, Qiu, Xiangguo, and Kobinger, Gary P
- Abstract
With the unprecedented scale of the 2014–2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. The road to effective and accessible antibody therapies against Ebola virus.
- Author
-
Fausther-Bovendo, Hugues and Kobinger, Gary
- Abstract
Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein
- Author
-
Roy, Soumitra, Kobinger, Gary P., Lin, Jianping, Figueredo, Joanita, Calcedo, Roberto, Kobasa, Darwyn, and Wilson, James M.
- Subjects
- *
INFLUENZA viruses , *RESPIRATORY infections , *NUCLEOPROTEINS , *EPITOPES - Abstract
Abstract: The development of adenoviral vectors based on non-human serotypes such as the chimpanzee adenovirus simian adenovirus 24 (AdC7) may allow for their utilization in populations harboring neutralizing antibodies to common human serotypes. Because adenoviral vectors can be used to generate potent T cell responses, they may be useful as vaccines against pandemic influenza such as may be caused by the H5N1 strains that are currently endemic in avian populations. The influenza nucleoprotein (NP) is known to provide MHC Class I restricted epitopes that are effective in evoking a cytolytic response. Because there is only low sequence variation in NP sequences between different influenza strains, a T cell vaccine may provide heterosubtypic protection against a spectrum of influenza A strains. An AdC7 vector expressing the influenza A/Puerto Rico/8/34 NP was tested for its efficacy in protecting BALB/c mice against two H5N1 strains and compared to a conventional human adenovirus serotype 5 vaccine. The AdC7 NP vaccine elicited a strong anti-NP T cell response. When tested in a mouse challenge model, there was improved survival following challenge with two strains of H5N1 that have caused human outbreaks, Vietnam/1203/04 and Hong Kong/483/97, although the improved survival reached statistical significance only with the strain from Vietnam. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
5. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques
- Author
-
Kobinger, Gary P., Figueredo, Joanita M., Rowe, Thomas, Zhi, Yan, Gao, Guangping, Sanmiguel, Julio C., Bell, Peter, Wivel, Nelson A., Zitzow, Lois A., Flieder, Douglas B., Hogan, Robert J., and Wilson, James M.
- Subjects
- *
SARS disease , *ADENOVIRUS diseases , *VACCINES , *PNEUMONIA prevention , *VACCINATION - Abstract
Abstract: A ferret model of severe acute respiratory syndrome (SARS)-CoV infection was used to evaluate the efficacy of an adenovirus vaccine. Animals were subjected to heterologous prime-boost using vectors from human serotype 5 and chimpanzee derived adenoviruses (human AdHu5 and chimpanzee AdC7) expressing spike protein followed by intranasal challenge with SARS-CoV. Vaccination led to a substantial reduction in viral load and prevented the severe pneumonia seen in unvaccinated animals. The same prime-boost strategy was effective in rhesus macaques in eliciting SARS-CoV specific immune responses. These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
6. Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease.
- Author
-
de La Vega, Marc-Antoine and Kobinger, Gary P
- Subjects
- *
EBOLA virus disease , *VESICULAR stomatitis , *VIRAL vaccines , *HUMORAL immunity , *ADENOVIRUS diseases , *EBOLA virus , *ANIMALS , *RNA viruses , *STOMATITIS , *BLIND experiment - Published
- 2020
- Full Text
- View/download PDF
7. Pharmacologically Regulated Regeneration of Functional Human Pancreatic Islets
- Author
-
Kobinger, Gary P., Deng, Shaoping, Louboutin, Jean-Pierre, Vatamaniuk, Marko, Rivera, Victor M., Lian, Moh-Moh, Markmann, James F., Clackson, Tim, Raper, Steven E., Matschinsky, Franz, and Wilson, James M.
- Subjects
- *
ISLANDS of Langerhans , *CARBOHYDRATE intolerance , *INSULIN , *CELL growth - Abstract
Abstract: Transplantation of allogeneic islets can correct the metabolic abnormalities of Type I diabetes. Limited availability of donor pancreas tissues restricts the application of this therapeutic modality to a subset of eligible recipients. In an attempt to expand the utility of available donor human pancreas tissue, we developed a method to stimulate the proliferation of insulin-secreting β-cells within human islets. A lentiviral vector was used to introduce into human islets chimeric signaling receptors that are activated to stimulate cell proliferation through interactions with a small-molecule drug called a chemical inducer of dimerization (CID). In vitro exposure of vector-transduced human islets to the CID expanded the number of cells and increased regulated insulin secretion. Transplantation of the regenerated islets into diabetic immunodeficient mice, followed by in vivo administration of the CID, corrected hyperglycemia. This strategy has the potential to reduce the quantity of human islets required for treatment of patients with Type I diabetes. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
8. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung
- Author
-
Fe Medina, Maria, Kobinger, Gary P., Rux, John, Gasmi, Mehdi, Looney, David J., Bates, Paul, and Wilson, James M.
- Subjects
- *
HIV , *GLYCOPROTEINS , *EPITHELIAL cells , *GENETIC transformation - Abstract
A human immunodeficiency virus (HIV)-based vector pseudotyped with the Ebola Zaire (EboZ) viral envelope glycoprotein (GP) was recently shown to transduce murine airway epithelia cells in vivo. In this study, the vector was further redesigned to improve gene transfer and also to increase safety. We used mutant EboZ envelopes for pseudotyping, which resulted in higher titers and increased transduction of airway cells in vivo compared to vectors pseudotyped with wild-type EboZ GP. As these envelopes lack regions associated with toxicity of the wild-type EboZ GP, they should also be safer to use for pseudotyping of lentiviral vectors. In addition, lentiviral vectors were created based on feline immunodeficiency virus and shown to have similar efficiency of transduction compared to HIV-based vectors. The creation of lentiviral vectors with highly engineered EboZ envelopes improved the performance of the system and should also increase its safety since only minimal regions of the EboZ envelope, which lack the toxic domain, are used. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
9. Efficient Transduction of Liver and Muscle after in Utero Injection of Lentiviral Vectors with Different Pseudotypes
- Author
-
MacKenzie, Tippi C., Kobinger, Gary P., Kootstra, Neeltje A., Radu, Antoneta, Sena-Esteves, Miguel, Bouchard, Sarah, Wilson, James M., Verma, Inder M., and Flake, Alan W.
- Subjects
- *
GENETIC transduction , *CYTOMEGALOVIRUSES - Abstract
In this study we investigate the efficacy of lentiviral vectors of different pseudotypes for gene transfer to tissues of the preimmune fetus. BALB/c fetuses at 14–15 days'' gestation received lentiviral vectors carrying the transgene lacZ under the control of the human cytomegalovirus (CMV) promoter by intramuscular (i.m.) or intrahepatic (i.h.) injection. We pseudotyped the lentiviral vectors with vesicular stomatitis virus (VSV-G), with Mokola virus, or with Ebola virus envelope glycoproteins. We harvested the pups at time points between 5 days and 9 months following injection and performed a detailed histologic assessment. The efficiency and distribution of transduction after in utero administration was highly dependent upon the route of administration and the pseudotype of vector used. Biodistribution studies showed widespread distribution of vector sequences in multiple tissues, albeit at very low levels, and transduced cells were found in significant numbers only in liver, heart, and muscle. Overall, VSV-G was the most efficient in transducing hepatocytes, whereas Mokola and Ebola were more efficient in transducing myocytes. Transduction of cardiomyocytes was observed after both i.m. and i.h. injection of all three vectors. Our findings of long-term transduction of skeletal myocytes and cardiomyocytes after in utero administration suggest a novel strategy for the treatment of congenital muscular dystrophies. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
10. Targeted Transduction Patterns in the Mouse Brain by Lentivirus Vectors Pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV Envelope Proteins
- Author
-
Watson, Deborah J., Kobinger, Gary P., Passini, Marco A., Wilson, James M., and Wolfe, John H.
- Subjects
- *
LENTIVIRUSES , *GENETIC vectors , *CENTRAL nervous system - Abstract
Lentiviral vectors have proven to be promising tools for transduction of central nervous system (CNS) cells in vivo and in vitro. In this study, CNS transduction patterns of lentiviral vectors pseudotyped with envelope glycoproteins from Ebola virus, murine leukemia virus (MuLV), lymphocytic choriomeningitis virus (LCMV), or the rabies-related Mokola virus were compared to a vector pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G). Mokola-, LCMV-, and VSV-G-pseudotyped vectors transduced similar populations, including striatum, thalamus, and white matter. Mokola-pseudotyped vectors were the most efficient of the three. MuLV-pseudotyped lentivirus efficiently transduced striatum and hippocampal dentate gyrus. In contrast, no transduction resulted from injection of Ebola-pseudotyped virus in the CNS. The same pattern was observed in vitro with primary cultured oligodendrocytes. LCMV, MuLV, and Ebola pseudotypes were the most stable. These results demonstrate that targeted transduction in the CNS can be achieved using specific envelope glycoproteins to pseudotype lentiviral vectors, and support the use of Mokola-pseudotyped and MuLV-pseudotyped lentiviral vectors as efficient and stable alternatives to VSV-G-pseudotyped vectors for experiments in the mouse CNS. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
11. 1092. Adenovirus-Based Vaccine Prevents Pneumonia in Ferrets Challenged with the SARS Coronavirus
- Author
-
Kobinger, Gary P., Rowe, Thomas, Gao, Guangping, Figueredo, Joanita M., Sanmiguel, Julio, Bell, Peter, Hogan, Robert J., and Wilson, James M.
- Subjects
- *
ADENOVIRUSES , *VIRAL vaccines - Abstract
An abstract of the article "Adenovirus-Based Vaccine Prevents Pneumonia in Ferrets Challenged with the SARS Coronavirus," by Gary P. Kobinger and colleagues is presented.
- Published
- 2005
- Full Text
- View/download PDF
12. 141. Adenovirus Vaccine to Ebola Virus: Mechanism of Protection and Impact of Pre-Existing Immunity to the Vaccine Carrier
- Author
-
Kobinger, Gary P., Feldmann, Heinz, Zhi, Yan, Schumer, Gregory, Gao, Guangping, Feldmann, Frederik, Jones, Steven, and Wilson, James M.
- Subjects
- *
ADENOVIRUSES , *VACCINATION - Abstract
An abstract of the article "Adenovirus Vaccine to Ebola Virus: Mechanism of Protection and Impact of Pre-Existing Immunity to the Vaccine Carrier," by Gary P. Kobinger, Heinz Feldmann, Yan Zhi, Gregory Schumer, Guangping Gao, Frederik Feldmann, Steven Jones, and James M. Wilson is presented.
- Published
- 2005
- Full Text
- View/download PDF
13. Progression of Ebola Therapeutics During the 2014–2015 Outbreak.
- Author
-
Mendoza, Emelissa J., Qiu, Xiangguo, and Kobinger, Gary P.
- Subjects
- *
DISEASE outbreaks , *THERAPEUTIC use of immunoglobulins , *TREATMENT effectiveness , *CLINICAL trials ,TREATMENT of Ebola virus diseases - Abstract
The recent Ebola virus (EBOV) outbreak in West Africa was the deadliest EBOV epidemic in history, highlighting the need for a safe and efficacious treatment against EBOV disease (EVD). In the absence of an approved treatment, experimental drugs were utilized under compassionate grounds hoping to diminish EVD-associated morbidity and mortality. As more data were collected from safety studies, Phase II/III clinical trials were introduced in Guinea, Sierra Leone, and Liberia to test promising candidates, including small-molecule drugs, RNA-based treatments, and antibody-based therapies. In this review, we summarize the use of, and preliminary observations from, current clinical trials with EVD therapeutics, shedding light on experimental drug selection, emergency clinical evaluation, and the impact these factors may have on future infectious disease outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity.
- Author
-
Babuadze, George Giorgi, Echanove, Jose, Lamarre, Claude, deLaVega, Marc-Antoine, Fausther-Bovendo, Hugues, Racine, Trina, M.Gomez, Alejandro, Azizi, Hiva, Wade, Mathew, Kozak, Robert, and Kobinger, Gary P.
- Subjects
- *
VIRAL antigens , *VACCINE effectiveness , *DNA , *GENE therapy , *DNA vaccines , *TRANSGENE expression - Abstract
The development of new, low-cost vaccines and effective gene therapies requires accurate delivery and high-level expression of candidate genes. We developed a plasmid vector, pIDV-II, that allows for both easy manipulation and high expression of exogenous genes in mammalian cells. This plasmid is based upon the pVax1 plasmid and shares a common structure with typical mammalian transcription units. It is composed of a chicken β-actin promoter (CAG), followed by an intron and flanked by two restriction sites, and also includes a post-transcriptional regulatory element, followed by a transcriptional termination signal. While the modification of pVax1 elements either decreased eGFP expression levels or had no effect at all, replacement of the promoter, the poly-A signal, deletion of the T7 and AmpR promoters, and inversion of the ORI-Neo/Kan cassette, significantly increased in vitro eGFP expression with the modified plasmid called pIDV-II. To further evaluate our vector, expression levels of three viral antigens were compared in cell lines transfected either with pVax1 or pCAGGS backbones as controls. Higher transgene expression was consistently observed with pIDV-II. The humoral and cellular responses generated in mice immunized with pIDV-II vs pVax1 expressing each viral antigen individually were superior by 2-fold or more as measured by ELISA and ELISPOT assays. Overall these results indicate that pIDV-II induces robust transgene expression, with concomitant improved cellular and humoral immune responses against the transgene of interest over pVax1. The new vector, pIDV-II, offers an additional alternative for DNA based vaccination and gene therapy for animal and human use. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.
- Author
-
Kudchodkar, Sagar B., Choi, Hyeree, Reuschel, Emma L., Esquivel, Rianne, Jin-Ah Kwon, Jackie, Jeong, Moonsup, Maslow, Joel N., Reed, Charles C., White, Scott, Kim, J. Joseph, Kobinger, Gary P., Tebas, Pablo, Weiner, David B., and Muthumani, Kar
- Subjects
- *
ZIKA virus infections , *DNA vaccines , *FLAVIVIRUSES , *DRUG development - Abstract
Abstract Vaccines are considered one of the greatest advances in modern medicine. The global burden of numerous infectious diseases has been significantly reduced, and in some cases, effectively eradicated through the deployment of specific vaccines. However, efforts to develop effective new vaccines against infectious pathogens such as influenza, Human immunodeficiency virus (HIV), dengue virus (DENV), chikungunya virus (CHIKV), Ebola virus, and Zika virus (ZIKV) have proven challenging. Zika virus is a mosquito-vectored flavivirus responsible for periodic outbreaks of disease in Africa, Southeast Asia, and the Pacific Islands dating back over 50 years. Over this period, ZIKV infections were subclinical in most infected individuals and resulted in mild cases of fever, arthralgia, and rash in others. Concerns about ZIKV changed over the past two years, however, as outbreaks in Brazil, Central American countries, and Caribbean islands revealed novel aspects of infection including vertical and sexual transmission modes. Cases have been reported showing dramatic neurological pathologies including microcephaly and other neurodevelopmental problems in babies born to ZIKV infected mothers, as well as an increased risk of Guillain-Barre syndrome in adults. These findings prompted the World Health Organization to declare ZIKV a public health emergency in 2016, which resulted in expanded efforts to develop ZIKV vaccines and immunotherapeutics. Several ZIKV vaccine candidates that are immunogenic and effective at blocking ZIKV infection in animal models have since been developed, with some of these now being evaluated in the clinic. Additional therapeutics under investigation include anti-ZIKV monoclonal antibodies (mAbs) that have been shown to neutralize infection in vitro as well as protect against morbidity in mouse models of ZIKV infection. In this review, we summarize the current understanding of ZIKV biology and describe our efforts to rapidly develop a vaccine against ZIKV. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
16. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.
- Author
-
Yan, Jian, Morrow, Matthew P., Chu, Jaemi S., Racine, Trina, Reed, Charles C., Khan, Amir S., Broderick, Kate E., Kim, J. Joseph, Kobinger, Gary P., Sardesai, Niranjan Y., and Weiner, David B.
- Subjects
- *
BLOOD agglutination , *INFLUENZA vaccines , *MORTALITY , *PATHOGENIC microorganisms , *ANTIGENS , *DISEASES - Abstract
Despite the routine development and distribution of seasonal influenza vaccines, influenza remains an important pathogen contributing to significant human morbidity as well as mortality each year. The seasonal variability of influenza creates a significant issue for vaccine development of seasonal strains that can afford protection from infection or disease based on serotype matching. It is appreciated that the globular head of the HA antigen contained in the vaccines generates antibodies that result in HAI activity that are a major correlates of the protection against a particular strain. Due to seasonal genetic changes in the HA protein, however, new vaccine strains are needed to be developed continually to match the new HA antigen of that seasons virus. A distinct advantage in seasonal vaccine development would be if a small group of antigens could be developed that could span many seasons without needed to be replaced due to this genetic drift. Here we report on a synthetic microconsensus approach that relies on a small collection of 4 synthetic H1HA DNA antigens which together induce broad protective HAI immunity spanning decades of H1 influenza viruses in mice, guinea pigs and non-human primates. The protective HAI titers induced by microconsensus immunogens are fully functional in vivo as immunized ferrets were completely protected from A/Mexico/InDRE4487/2009 virus infection and morbidity associated with lethal challenge. These results are encouraging that a limited easy-to-formulate collection of invariant antigens can be developed which can span seasonal vaccine changes allowing for continued immune protection. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Nanozyme-strip for rapid local diagnosis of Ebola.
- Author
-
Duan, Demin, Fan, Kelong, Zhang, Dexi, Tan, Shuguang, Liang, Mifang, Liu, Yang, Zhang, Jianlin, Zhang, Panhe, Liu, Wei, Qiu, Xiangguo, Kobinger, Gary P., Fu Gao, George, and Yan, Xiyun
- Subjects
- *
EBOLA virus disease , *NANOPARTICLES , *VIRUS-induced enzymes , *VIRAL vaccines , *MAGNETIC nanoparticles , *DIAGNOSIS - Abstract
Ebola continues to rage in West Africa. In the absence of an approved vaccine or treatment, the priority in controlling this epidemic is to promptly identify and isolate infected individuals. To this end, a rapid, highly sensitive, and easy-to-use test for Ebola diagnosis is urgently needed. Here, by using Fe 3 O 4 magnetic nanoparticle (MNP) as a nanozyme probe, we developed a MNP-based immunochromatographic strip (Nanozyme-strip), which detects the glycoprotein of Ebola virus (EBOV) as low as 1 ng/mL, which is 100-fold more sensitive than the standard strip method. The sensitivity of the Nanozyme-strip for EBOV detection and diagnostic accuracy for New Bunyavirus clinical samples is comparable with ELISA, but is much faster (within 30 min) and simpler (without need of specialist facilities). The results demonstrate that the Nanozyme-strip test can rapidly and sensitively detect EBOV, providing a valuable simple screening tool for diagnosis of infection in Ebola-stricken areas. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Long-Term Correction of Sandhoff Disease Following Intravenous Delivery of rAAV9 to Mouse Neonates.
- Author
-
Walia, Jagdeep S, Altaleb, Naderah, Bello, Alexander, Kruck, Christa, LaFave, Matthew C, Varshney, Gaurav K, Burgess, Shawn M, Chowdhury, Biswajit, Hurlbut, David, Hemming, Richard, Kobinger, Gary P, and Triggs-Raine, Barbara
- Subjects
- *
SANDHOFF disease , *INTRAVENOUS catheterization complications , *NEONATAL diseases , *ANTISENSE DNA , *NEUROLOGY - Abstract
GM2 gangliosidoses are severe neurodegenerative disorders resulting from a deficiency in β-hexosaminidase A activity and lacking effective therapies. Using a Sandhoff disease (SD) mouse model (Hexb−/−) of the GM2 gangliosidoses, we tested the potential of systemically delivered adeno-associated virus 9 (AAV9) expressing Hexb cDNA to correct the neurological phenotype. Neonatal or adult SD and normal mice were intravenously injected with AAV9-HexB or -LacZ and monitored for serum β-hexosaminidase activity, motor function, and survival. Brain GM2 ganglioside, β-hexosaminidase activity, and inflammation were assessed at experimental week 43, or an earlier humane end point. SD mice injected with AAV9-LacZ died by 17 weeks of age, whereas all neonatal AAV9-HexB-treated SD mice survived until 43 weeks (P < 0.0001) with only three exhibiting neurological dysfunction. SD mice treated as adults with AAV9-HexB died between 17 and 35 weeks. Neonatal SD-HexB-treated mice had a significant increase in brain β-hexosaminidase activity, and a reduction in GM2 ganglioside storage and neuroinflammation compared to adult SD-HexB- and SD-LacZ-treated groups. However, at 43 weeks, 8 of 10 neonatal-HexB injected control and SD mice exhibited liver or lung tumors. This study demonstrates the potential for long-term correction of SD and other GM2 gangliosidoses through early rAAV9 based systemic gene therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
- Author
-
Wong, Gary, Audet, Jonathan, Fernando, Lisa, Fausther-Bovendo, Hugues, Alimonti, Judie B., Kobinger, Gary P., and Qiu, Xiangguo
- Subjects
- *
VESICULAR stomatitis , *VIRAL vaccines , *EBOLA virus disease , *HEMORRHAGIC fever , *IMMUNIZATION , *GLYCOPROTEINS , *LABORATORY rodents , *EPIDEMICS , *VACCINATION - Abstract
Ebola virus (EBOV) infections cause lethal hemorrhagic fever in humans, resulting in up to 90% mortality. EBOV outbreaks are sporadic and unpredictable in nature; therefore, a vaccine that is able to provide durable immunity is needed to protect those who are at risk of exposure to the virus. This study assesses the long-term efficacy of the vesicular stomatitis virus (VSV)-based vaccine (VSVΔG/EBOVGP) in two rodent models of EBOV infection. Mice and guinea pigs were first immunized with 2 × 10 4 or 2 × 10 5 plaque forming units (PFU) of VSVΔG/EBOVGP, respectively. Challenge of mice with a lethal dose of mouse-adapted EBOV (MA-EBOV) at 6.5 and 9 months after vaccination provided complete protection, and 80% (12 of 15 survivors) protection at 12 months after vaccination. Challenge of guinea pigs with a lethal dose of guinea pig-adapted EBOV (GA-EBOV) at 7, 12 and 18 months after vaccination resulted in 83% (5 of 6 survivors) at 7 months after vaccination, and 100% survival at 12 and 18 months after vaccination. No weight loss or clinical signs were observed in the surviving animals. Antibody responses were analyzed using sera from individual rodents. Levels of EBOV glycoprotein-specific IgG antibody measured immediately before challenge appeared to correlate with protection. These studies confirm that vaccination with VSVΔG/EBOVGP is able to confer long-term protection against Ebola infection in mice and guinea pigs, and support follow-up studies in non-human primates. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Post-exposure therapy of filovirus infections.
- Author
-
Wong, Gary, Xiangguo Qiu, Olinger, Gene G., and Kobinger, Gary P.
- Subjects
- *
VIRUS diseases , *FILOVIRIDAE , *HEMORRHAGIC fever , *MONOCLONAL antibodies , *SYMPTOMS , *MICROBIAL virulence , *DISEASE progression - Abstract
Filovirus infections cause fatal hemorrhagic fever characterized by the initial onset of general symptoms before rapid progression to severe disease; the most virulent species can cause death to susceptible hosts within 10 days after the appearance of symptoms. Before the advent of monoclonal antibody (mAb) therapy, infection of nonhuman primates (NHPs) with the most virulent filovirus species was fatal if interventions were not administered within minutes. A novel nucleoside analogue, BCX4430, has since been shown to also demonstrate protective efficacy with a delayed treatment start. This review summarizes and evaluates the potential of current experimental candidates for treating filovirus disease with regard to their feasibility and use in the clinic, and assesses the most promising strategies towards the future development of a pan-filovirus medical countermeasure. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.
- Author
-
Yan, Jian, Villarreal, Daniel O., Racine, Trina, Chu, Jaemi S., Walters, Jewell N., Morrow, Matthew P., Khan, Amir S., Sardesai, Niranjan Y., Kim, J. Joseph, Kobinger, Gary P., and Weiner, David B.
- Subjects
- *
H7N9 Influenza , *INFLUENZA vaccines , *DNA vaccines , *IMMUNE response , *VIRAL envelope proteins , *HEMAGGLUTININ - Abstract
Abstract: Despite an intensive vaccine program influenza infections remain a major health problem, due to the viruses’ ability to change its envelope glycoprotein hemagglutinin (HA), through shift and drift, permitting influenza to escape protection induced by current vaccines or natural immunity. Recently a new variant, H7N9, has emerged in China causing global concern. First, there have been more than 130 laboratory-confirmed human infections resulting in an alarmingly high death rate (32.3%). Second, genetic changes found in H7N9 appear to be associated with enabling avian influenza viruses to spread more effectively in mammals, thus transmitting infections on a larger scale. Currently, no vaccines or drugs are effectively able to target H7N9. Here, we report the rapid development of a synthetic consensus DNA vaccine (pH7HA) to elicit potent protective immunity against the H7N9 viruses. We show that pH7HA induces broad antibody responses that bind to divergent HAs from multiple new members of the H7N9 family. These antibody responses result in high-titer HAI against H7N9. Simultaneously, this vaccine induces potent polyfunctional effector CD4 and CD8T cell memory responses. Animals vaccinated with pH7HA are completely protected from H7N9 virus infection and any morbidity associated with lethal challenge. This study establishes that this synthetic consensus DNA vaccine represents a new tool for targeting emerging infection, and more importantly, its design, testing and development into seed stock for vaccine production in a few days in the pandemic setting has significant implications for the rapid deployment of vaccines protecting against emerging infectious diseases. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
22. Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and Ebola.
- Author
-
Shedlock, Devon J, Aviles, Jenna, Talbott, Kendra T, Wong, Gary, Wu, Stephan J, Villarreal, Daniel O, Myles, Devin JF, Croyle, Maria A, Yan, Jian, Kobinger, Gary P, and Weiner, David B
- Subjects
- *
CYTOTOXIC T cells , *T cells , *DNA vaccines , *VACCINES , *MARBURG virus - Abstract
Marburg and Ebola hemorrhagic fevers have been described as the most virulent viral diseases known to man due to associative lethality rates of up to 90%. Death can occur within days to weeks of exposure and there is currently no licensed vaccine or therapeutic. Recent evidence suggests an important role for antiviral T cells in conferring protection, but little detailed analysis of this response as driven by a protective vaccine has been reported. We developed a synthetic polyvalent-filovirus DNA vaccine against Marburg marburgvirus (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SUDV). Preclinical efficacy studies were performed in guinea pigs and mice using rodent-adapted viruses, whereas murine T-cell responses were extensively analyzed using a novel modified assay described herein. Vaccination was highly potent, elicited robust neutralizing antibodies, and completely protected against MARV and ZEBOV challenge. Comprehensive T-cell analysis revealed cytotoxic T lymphocytes (CTLs) of great magnitude, epitopic breadth, and Th1-type marker expression. This model provides an important preclinical tool for studying protective immune correlates that could be applied to existing platforms. Data herein support further evaluation of this enhanced gene-based approach in nonhuman primate studies for in depth analyses of T-cell epitopes in understanding protective efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. The Endogenous Protease Inhibitor TIMP-1 Mediates Protection and Recovery from Cutaneous Photodamage.
- Author
-
Yokose, Urara, Hachiya, Akira, Sriwiriyanont, Penkanok, Fujimura, Tsutomu, Visscher, Marty O, Kitzmiller, William J, Bello, Alexander, Tsuboi, Ryoji, Kitahara, Takashi, Kobinger, Gary P, and Takema, Yoshinori
- Subjects
- *
PROTEASE inhibitors , *TISSUE inhibitors of metalloproteinases , *SKIN disease treatment , *THERAPEUTIC use of ultraviolet radiation , *EXTRACELLULAR matrix , *MATRIX metalloproteinases , *QUALITATIVE research - Abstract
UVB exposure is well known to induce skin photodamage and photoaging that correlates with qualitative and quantitative deterioration of the dermal extracellular matrix (ECM) because of the upregulation of matrix metalloproteinases (MMPs). Although inhibitory effects of tissue inhibitor of metalloproteinases (TIMPs) on most MMPs have been reported, the protective role of TIMP-1 against photodamage is poorly understood. To address this, TIMP-1 function was augmented or abolished in a human skin xenograft photodamage model after the confirmation of significantly diminished TIMP-1 expression both in photoaged and intrinsically aged skins. During a chronic UVB exposure regimen, pre-treatment with a lentiviral vector overexpressing TIMP-1 or concomitant administration of an anti-TIMP-1-neutralizing antibody (NAB) led to photoprotection or more severe photodamage, respectively. Overexpression of TIMP-1 resulted in significant inhibition of UVB-induced ECM degradation, as well as suppression of decreased skin elasticity and roughness, whereas the NAB-mediated inhibition of TIMP-1 had opposite effects. Furthermore, UVB-induced production of the pro-inflammatory cytokine, tumor necrosis factor α, was inhibited by TIMP-1 treatment of human keratinocytes. Taken together, these data shed light on the important role of TIMP-1 in protection and recovery from cutaneous photodamage because of its suppression of ECM degradation and inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection
- Author
-
Patel, Ami, Gray, Michael, Li, Yan, Kobasa, Darwyn, Yao, Xiaojian, and Kobinger, Gary P.
- Subjects
- *
DNA vaccines , *INFLUENZA A virus, H5N1 subtype , *ANTIGENS , *GENE expression , *IMMUNITY , *IMMUNE response , *T cells , *PROTEINS - Abstract
Abstract: Achieving broad-spectrum immunity against emerging zoonotic viruses such as avian influenza H5N1 and other possible pandemic viruses will require generation of cross-protective immune responses. Strong antibody responses generated against the H5HA protein are protective, however, antigenic variation between diverging isolates can interfere with virus neutralization. The current study investigates co-administration of an H5 HA DNA vaccine with other variable and conserved influenza antigens (NA, NP, and M2). All antigens were derived from the A/Hanoi/30408/2005 (H5N1) virus and the contribution towards overall protection and immune activation was assessed against lethal homologous and heterologous challenges. An (HA+NA) combination afforded the best protection against homologous challenge and (HA+NP) was comparable to HA alone against heterologous A/Hong Kong/483/1997 challenge. Interestingly, combining all four H5 antigens at a single site did not improve protection against matched challenge and unexpectedly reduced survival by 30% against a heterologous challenge. Survival was also significantly decreased against heterologous challenge following combination of (HA+NP) with an unrelated antigen. Although there were no significant changes in antibody titres, significantly lower T-cell responses were detected against all antigens except HA in each combination. Co-administration of the vaccines at different injection sites restored T-cell responses but did not improve overall protection. Similar observations were also recorded following combination of HA and NP antigens using two different adenovirus-based backbones. Overall, the data suggest that co-administering certain H5N1 antigens offer better or comparable protection to HA alone, however, combining extra antigens may be unnecessary and lead to unfavourable immune responses. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
25. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets
- Author
-
Pillet, Stéphane, Kobasa, Darwyn, Meunier, Isabelle, Gray, Michael, Laddy, Dominick, Weiner, David B., von Messling, Veronika, and Kobinger, Gary P.
- Subjects
- *
CELLULAR immunity , *IMMUNE response , *IMMUNOGLOBULINS , *INFLUENZA , *PATHOGENIC microorganisms , *DRUG development , *HEMAGGLUTININ , *FERRETS as laboratory animals - Abstract
Abstract: The identification of immune correlates of protection against highly pathogenic human-adapted influenza is instrumental in the development of the next generation of vaccines. Towards this, ferrets received either one dose of a conventionally produced vaccine, two inoculations of a hemagglutinin (HA)-expressing DNA vaccine, or a prime-boost regimen of the DNA vaccine followed by injection of a HA-expressing adenoviral vector. In addition to the antibody response, ferret-specific interferon-gamma (IFN-γ) ELISpot and flow cytometry assays were developed to follow the cellular immune response. Animals that received the conventional vaccine mounted a humoral response, while the DNA vaccinated groups also developed IFN-γ producing T cells. Upon challenge with the matched highly pathogenic A/South Carolina/1/18 H1N1 influenza A virus, the conventionally vaccinated group developed moderate to severe signs of disease, whereas the DNA vaccinated animals experienced mild disease. In the presence of an antibody response within the protective range, the extent of the T cell response correlated more accurately with reduced morbidity in vaccinated ferrets. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
26. Effects of IGF-Binding Protein 5 in Dysregulating the Shape of Human Hair.
- Author
-
Sriwiriyanont, Penkanok, Hachiya, Akira, Pickens, William L., Moriwaki, Shigeru, Kitahara, Takashi, Visscher, Marty O., Kitzmiller, William J., Bello, Alexander, Takema, Yoshinori, and Kobinger, Gary P.
- Subjects
- *
INSULIN-like growth factor-binding proteins , *HAIR follicles , *LABORATORY animals , *XENOGRAFTS , *FUNCTIONAL analysis , *MORPHOGENESIS - Abstract
The hair follicle has a unique dynamic property to cyclically regenerate throughout life. Despite significant progress in hair structure and hair shape determination using animal models, the mechanisms controlling the architecture and the shape of the human hair remain largely unexplored. In this study, comparison of the genetic expression of several human genes, especially those involved in growth, development, and differentiation, between Caucasian curly hair and naturally straight hair was performed. Thereafter, analyses using human recombinant and lentiviral vector technologies were conducted to further dissect and elucidate a molecular mechanism that regulates hair growth and development, particularly in controlling the shape of the hair shaft. Overexpression of IGF-binding protein 5 (IGFBP-5) in the human hair xenografts obtained from straight- and curly-haired individuals was found to result in the decreased expression of several extracellular matrix proteins and disassembly of adhesional junctions, resulting in twisted hair shafts as well as an unusual deposition of hair cuticle that may be derived from the disturbance of normal proliferation and differentiation. This study provides evidence that IGFBP-5 has an effect on human hair shape, and that lentiviral transduction regimen can be used for functional analysis of genes involved in human hair morphogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
27. Lentiviral Vector-Mediated Gene Transfer to Human Hair Follicles.
- Author
-
Sriwiriyanont, Penkanok, Hachiya, Akira, Pickens, William L., Moriwaki, Shigeru, Ohuchi, Atsushi, Kitahara, Takashi, Takema, Yoshinori, Kitzmiller, William J., Visscher, Marty O., Bello, Alexander, Tsuboi, Ryoji, and Kobinger, Gary P.
- Subjects
- *
LETTERS to the editor , *TRANSDERMAL medication - Abstract
A letter to the editor is presented in response to the article on the role of human hair follicles in transdermal drug delivery that was published in the previous.
- Published
- 2009
- Full Text
- View/download PDF
28. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses
- Author
-
Patel, Ami, Tran, Kaylie, Gray, Michael, Li, Yan, Ao, Zhujun, Yao, Xiaojian, Kobasa, Darwyn, and Kobinger, Gary P.
- Subjects
- *
VIRAL antigens , *INFLUENZA viruses , *DNA vaccines , *HEMAGGLUTININ , *IMMUNIZATION , *IMMUNE response , *NEURAMINIDASE , *LABORATORY mice , *AVIAN influenza vaccines - Abstract
Abstract: The combination of rapid evolution and high mortality in human cases of infections has raised concerns that the H5N1 avian influenza virus may become a new, possibly severe, pandemic virus. Vaccination is likely to be the most efficient strategy to mitigate the impact of the next influenza pandemic. The present study evaluates B and T cell immune responses generated by the H5N1 viral antigens, hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), or the M2 ion channel in parallel, expressed from a DNA vaccine vehicle. Protection studies of immunized mice challenged with 100 LD50 of homologous or heterologous H5N1 viruses indicate that HA afforded better protection than the NA, NP or M2 DNA vaccines. The antibody response was also higher in HA-vaccinated mice as determined by hemagglutination inhibition (HI) and neutralizing antibodies (NAB) assays. Interestingly, the T cell response was higher against HA than against NA, NP or M2 and was detectable at low doses of the DNA–HA vaccine capable of inducing complete protection, despite the absence of a detectable B cell response. This study emphasizes the need to evaluate the relationship between both arms of the adaptive immune responses in regards to protective efficacy against influenza virus. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
29. Immunogenicity of novel consensus-based DNA vaccines against avian influenza
- Author
-
Laddy, Dominick J., Yan, Jian, Corbitt, Natasha, Kobasa, Darwyn, Kobinger, Gary P., and Weiner, David B.
- Subjects
- *
INFLUENZA , *VIRUS diseases , *VACCINATION , *DNA vaccines - Abstract
Abstract: The frequency of H5N1 avian influenza outbreaks in China and Eastern Europe has raised concern in the world health community regarding the potential for an influenza pandemic. Efforts to monitor the disease will only provide minimal warning in a global society, and steps must be taken to prevent the morbidity and mortality associated with past pandemics. The current stockpiling of antibody-inducing “bird flu” vaccines assumes the strain that emerges will be the same as strains currently circulating. We propose a novel consensus-based approach to vaccine development, employing a DNA vaccine strategy that can provide more highly cross-reactive cellular immunity against lethal influenza infection. We show such constructs can induce strong cellular immunity against H5 influenza antigens. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
30. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
- Author
-
Wong, Gary, Richardson, Jason S., Cutts, Todd, Qiu, Xiangguo, and Kobinger, Gary P.
- Subjects
- *
VIRAL vaccines , *EBOLA viral disease transmission , *ADENOVIRUSES , *DRUG dosage , *INTRAMUSCULAR injections , *DRUG efficacy , *GUINEA pigs as laboratory animals , *EBOLA virus disease prevention - Abstract
Experimental Ebola virus (EBOV) vaccines have previously been shown to protect animals against a high dose intramuscular (IM) challenge, which is seen as a stringent challenge model. However, the protective efficacy against other modes of infection, such as contact with infectious hosts, is unknown. Using a previously established EBOV transmission animal model, we evaluated the efficacy of an adenovirus-based EBOV vaccine given to guinea pigs (gps) 4 weeks before direct contact with untreated, infectious animals. Prior vaccination resulted in robust levels of EBOV-specific antibodies and conferred complete protection in gps. These results support the use of vaccines to prevent EBOV transmission between hosts. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
31. Modeling host-feeding preference and molecular systematics of mosquitoes in different ecological niches in Canada.
- Author
-
Shahhosseini, Nariman, Frederick, Christina, Racine, Trina, Kobinger, Gary P., and Wong, Gary
- Subjects
- *
ECOLOGICAL niche , *MOSQUITOES , *CULEX pipiens , *TAMIASCIURUS , *AEDES aegypti , *GENETIC barcoding - Abstract
• This is the first work to analyze the host-feeding pattern of different mosquito species in Canada via molecular techniques. • We found 34 different mosquito taxa in Canada by combining morphological and molecular identification approaches. • Our data showed that the 201 blood-fed mosquitos were spread over 20 taxa who fed on 10 mammalian species, and three bird species. • The majority of all analysed mosquito taxa fed on humans (24.3%) followed by pigs (21.8%). • In our study, seven mosquito species with both ornithophilic and anthropophilic biting habit could function as potential bridge vectors. Several mosquito-borne viruses (mobovirus) cause infections in Canada. Ecological data on mosquito species and host range in Canada remains elusive. The main aim of the current study is to determine the host range and molecular systematics of mosquito species in Canada. Mosquitoes were collected using BG-Sentinel traps and aspirators at 10 trapping sites in Canada during 2018 and 2019. Mosquitoes collected were identified via morphology and molecular techniques. Mosquito sequences were aligned by MUSCLE algorithm and evolutionary systematics were drawn using MEGA and SDT software. Moreover, the source of blood meals was identified using a DNA barcoding technique. A total of 5,708 female mosquitoes over 34 different taxa were collected. DNA barcodes and evolutionary tree analysis confirmed the identification of mosquito species in Canada. Of the total collected samples, 201 specimens were blood-fed female mosquitoes in 20 different taxa. Four mosquito species represented about half (51.47%) of all collected blood-fed specimens: Aede cinereus (39 specimens, 19.11%), Aedes triseriatus (23, 11.27%), Culex pipiens (22, 10.78%), and Anopheles punctipennis (21, 10.29%). The most common blood meal sources were humans (49 mosquito specimens, 24% of all blood-fed mosquito specimen), pigs (44, 21.5%), American red squirrels (28, 13.7%), white-tailed deers (28, 13.7%), and American crows (16, 7.8%). Here, we present the first analysis of the host-feeding preference of different mosquito species in Canada via molecular techniques. Our results on mosquito distribution and behavior will aid in the development of effective mitigation and control strategies to prevent or reduce human/animal health issues in regards to moboviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. 595. Nasal Delivery of Adenovirus Expressing the Ebola Glycoprotein Protects Mice Against Ebola Virus in the Presence of Preexisting Immunity to the Vaccine Carrier.
- Author
-
Croyle, Maria, Feldmann, Heinz, Jones, Steven, Wilson, James M., and Kobinger, Gary P.
- Subjects
- *
ADENOVIRUSES , *BIOTERRORISM , *T cells , *IMMUNIZATION , *BODY weight , *VIRUS diseases - Abstract
The Ebola hemorrhagic fever virus has drawn increasing interest in the past years due to an augmentation in the number of natural outbreaks and its potential use as a bioterror agent. To date, only vaccine based on Vesicular Stomatitis virus and Adenovirus as the vaccine carrier have successfully protected nonhuman primates against a lethal dose of Ebola virus. Adenovirus vector derived from human adenovirus serotype 5 (AdHu5) has the advantage of having a well document track record following in vivo administration to thousand of individuals in different clinical trials. However, natural exposure to Adenovirus may result in the generation of a potent immunity capable of compromising adenovirus-based vaccine efficacy. 30 to 50% of the human population in North America has levels of serum antibodies that can neutralize relatively high doses of AdHu5. The present study evaluated mucosal vaccination of mice with AdHu5 expressing the Ebola glycoprotein (Ad-EboGP) and the impact of pre-existing immunity to the Adenovirus vector on vaccine efficacy. Intramuscular (I.M.), oral or nasal administration of Ad-EboGP fully protected mice against a lethal challenge with mouse-adapted Ebola virus. However, oral or I.M. vaccination of mice pretreated with pooled human antibodies, mimicking the presence of pre-existing immunity as evidenced by neutralizing antibody (NAB) to AdHu5 in mice sera, resulted in 0 to 10% survival after challenge with mouse-adapted Ebola virus. Interestingly, nasalvaccination with Ad-EboGP was protective even in the presence of preexisting immunity and resulted in 100% survival with no weight loss after challenge with Ebola virus. In untreated mice, T (INF-γ positive CD8 T cells following peptide re-stimulation) and B cell (NAB) responses were detected in all EboGP vaccinated groups although both responses were lower in mice receiving oral or nasal immunization when compared to mice administered I.M.. The presence of pre-existing immunity severely compromised the T and B cell responses in mice vaccinated orally or I.M. but not in mice receiving nasal immunization. Interestingly, PEGylation of the adenovirus vector partially rescued the B cell response but diminished the T cell response after oral vaccination of mice with pre-existing immunity and failed to improve survival. This study highlights the importance of vaccine delivery routes with regards to efficacy in the presence or absence of pre-existing immunity and provides new evidence for successful vaccination with AdHu5 and possibly readministration.Molecular Therapy (2006) 13, S230–S230; doi: 10.1016/j.ymthe.2006.08.669 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.